HER-1/HER-2在膀胱癌中的表达及阿法替尼对膀胱癌T24细胞影响的实验研究
|
摘要
第一章膀胱癌组织HER-1/HER-2的表达及其临床意义
目的研究膀胱移行细胞癌中HER-1和HER-2的表达情况,探讨HER-1和HER-2的表达与肿瘤的分期、病理分级等临床参数的关系。
方法采用免疫组化染色的方法研究56例膀胱移行细胞癌的手术肿瘤标本以及10例正常膀胱组织标本的HER-1和HER-2的表达,并进行分析研究HER-1和HER-2在膀胱肿瘤中的表达是否存在相关性,同时采用统计学分析HER-1和HER-2的表达与与肿瘤分期、病理分级等临床参数之间的关系
结果56例膀胱移行细胞癌患者的HER-1表达阳性率为55.4%,明显高于正常膀胱组织中HER-1的阳性率(10%)；HER-2在膀胱肿瘤的表达阳性率为37.5%,也明显高于正常膀胱组织中HER-1的阳性率(0%)。HER-1和HER-2在膀胱癌组织中的表达为正相关性。HER-1在高分期肿瘤(T3-T4)中的阳性率显著高于低分期肿瘤(T1-T2)(67.6%vs.36.4%),在高分级肿瘤(G3)中的阳性率显著高于低分期肿瘤(G1-G2)(72.7%vs.30.4%),在复发者中的阳性率显著高于初发组(75.0%vs.29.2%)。HER-2在高分期肿瘤(T3-T4)中的阳性率显著高于低分期肿瘤(T1-T2)(52.9%vs.13.6%),在复发者中的阳性率显著高于初发组(53.1%vs.16.7%)。
结论HER-1和HER-2均在膀胱移行细胞癌中表达异常增加,其两者的表达为正相关性。HER-1的表达与膀胱尿路上皮癌的临床分期、病理分级、肿瘤复发相关。HER-2的表达与膀胱尿路上皮癌的临床分期和肿瘤复发相关。
第二章HER-1和HER-2双重酪氨酸激酶抑制剂Afatinib对膀胱癌T24细胞生物学行为的影响
目的研究Afatinib对T24细胞增殖、凋亡和侵袭能力的影响。
方法采用不同浓度的Afatinib (0,1,5,10,20umol/L)作用T24细胞,用MTT法研究Afatinib对T24细胞的增殖能力的影响；用流式细胞术(FCM)检测Afatinib对人膀胱癌T24细胞凋亡的影响；用细胞粘附实验检测Afatinib对人膀胱癌T24细胞对FN粘附的影响；用Transwell实验研究Afatinib对T24细胞的侵袭能力的影响；同时用western blot检测了侵袭相关蛋白MMP-2与MMP-9表达及凋亡相关蛋白Bcl-2与Bax的表达,通过检查ERK1/2和Akt探讨Afatinib作用于膀胱癌的机制。
结果Afatinib对膀胱癌T24细胞的增殖能力有着抑制作用；对T24细胞有着促进凋亡的作用,并且能改变T24细胞Bcl-2与Bax蛋白含量之比；Afatinib对膀胱癌T24细胞的侵袭能力有着抑制的作用,能抑制T24细胞MMP-2及MMP-9蛋白的表达；Afatinib作用于膀胱癌T24细胞后,p-ERK1/2和p-Akt蛋白呈下降趋势,且呈剂量依赖性；而对T24细胞的t-ERK1/2和t-Akt蛋白无影响。
结论Afatinib抑制了T24细胞的增殖和侵袭能力,促进了T24细胞的凋亡。
第三章Afatinib对膀胱癌T24细胞顺铂化疗敏感性研究
目的探讨Afatinib与顺铂联合应用于膀胱癌细胞的协同作用,并对其作用机制及耐药性进行初步探讨。
方法先进行膀胱癌T24-ADM细胞的制备,用MTT法观察Afatinib联合顺铂对T24细胞增殖的抑制作用；分别用MTT法检测Afatinib作用前后顺铂对T24-ADM细胞增殖的抑制作用；PCR法检测Afatinib作用前后顺铂对T24-ADM细胞MDR-1基因mRNA的表达水平；用western-blot法检测Afatinib作用前后顺铂对T24-ADM细胞p-gp的表达水平。
结果Afatinib和顺铂联合用药的T24细胞的增殖抑制率高于单用顺铂；顺铂对Afatinib作用后的T24-ADM细胞抑制率高于Afatinib作用前；经Afatinib作用后,mdr-1基因的表达和p-gp蛋白的水平都有下调。
结论Afatinib与顺铂同时作用膀胱癌T24细胞时,两者在抑制T24细胞增殖上表现出协同作用,Afatinib作用后顺铂对于膀胱T24-ADM细胞的抑制率高于单独用顺铂的抑制率,Afatinib能够有效抑制mdr-1基因的表达和p-gp蛋白的水平。
Part one The correlation between expression of HER-1/HER-2in bladder transitional cell carcinoma(BTCC) and clinical significance
Aim Explore the situation of expression of HER-1/HER-2in BTCC and evaluate the correlation between HER-1/HER-2with the parameters of BTCC such as tumor stage and grade.
Method The expression level of HER-1/HER-2was estimated by Immunohistochemistry technique. And the influence factors were also tested.
Result The positive rate of HER-1expression among56patients was55.4%, which was distinct higher than that in normal bladder tissue (10%); the positive rate of HER-2expression among56patients was37.5%, which was distinct higher than that in normal bladder tissue (0%); The expression level of HER-1was obvious greater in high stage group, high grade and relapse group than that in low stage group, low grade group and primary group. The expression level of HER-2was obvious greater in high stage group and relapse group than that in low stage group and primary group.
Conclusion The expression of HER-1/HER-2was up-regulated in BTCC, and their expression has the positive correlation.
Part two The influence of Afatinib on T24cells'biologic behavior
Aim Estimate the influence of Afatinib on T24cells'biologic behavior such as invasion, proliferation and apoptosis.
Method The T24cell was grouped depend on the concentration of Afatinib treatment (0,1,5,10,20umol/L). MTT was employed to evaluate the impact of Afatinib to T24proliferation; FCM was employed to evaluate the impact of Afatinib to T24with apoptosis ability; transwell analysis was used to detect the effect of Afatinib to T24invasion. The invasion associated protein MMP-2and MMP-9, the apoptosis associated protein Bcl-2and Bax was detected by western blot. Check the ERK1/2and Akt to explore the mechanism of the Afatinib in bladder cancer.
Result The T24cells showed more powerful repression of proliferation and invasion under the treatment of Afatinib. Afatinib could regulate the expression of MMP-2/MMP-9and BAX/Bcl-2proteins. Afatinib could promote the apoptosis ability of T24.
Conclusion Afatinib inhibition of T24cell proliferation and invasion and promotes apoptosis in T24cells.
Part three Afatinib influencing chemotherapy sensibility that cisplatin treat T24cell
Aim To research Afatinib influencing chemotherapy sensibility that cisplatin treat T24cell
Method First we prepared the T24-ADM cell, then observation of Afatinib combined with cisplatin on the inhibition of T24by MTT. Using the MTT to test sensibility of cisplatin before and after Afatinib used in T24-ADM cell. Using the PCR to test MDR-1before and after Afatinib used in T24-ADM cell and using the western-blot to test p-gp before and after Afatinib used in T24-ADM cell.
Result Combining Afatinib and cisplatin could of inhibit T24cell proliferation better than with cisplatin alone; cisplatin could of inhibit T24cell proliferation better if the Afatinib was used. Afatinib can inhibit the mdr-1gene and P-gp protein.
Conclusion Afatinib and cisplatin showed a synergistic effect in the inhibition of T24cell proliferation. Cisplatin could of inhibit T24cell proliferation better if the Afatinib was used. Afatinib can inhibit the mdr-1gene and P-gp protein.
目的研究膀胱移行细胞癌中HER-1和HER-2的表达情况,探讨HER-1和HER-2的表达与肿瘤的分期、病理分级等临床参数的关系。
方法采用免疫组化染色的方法研究56例膀胱移行细胞癌的手术肿瘤标本以及10例正常膀胱组织标本的HER-1和HER-2的表达,并进行分析研究HER-1和HER-2在膀胱肿瘤中的表达是否存在相关性,同时采用统计学分析HER-1和HER-2的表达与与肿瘤分期、病理分级等临床参数之间的关系
结果56例膀胱移行细胞癌患者的HER-1表达阳性率为55.4%,明显高于正常膀胱组织中HER-1的阳性率(10%)；HER-2在膀胱肿瘤的表达阳性率为37.5%,也明显高于正常膀胱组织中HER-1的阳性率(0%)。HER-1和HER-2在膀胱癌组织中的表达为正相关性。HER-1在高分期肿瘤(T3-T4)中的阳性率显著高于低分期肿瘤(T1-T2)(67.6%vs.36.4%),在高分级肿瘤(G3)中的阳性率显著高于低分期肿瘤(G1-G2)(72.7%vs.30.4%),在复发者中的阳性率显著高于初发组(75.0%vs.29.2%)。HER-2在高分期肿瘤(T3-T4)中的阳性率显著高于低分期肿瘤(T1-T2)(52.9%vs.13.6%),在复发者中的阳性率显著高于初发组(53.1%vs.16.7%)。
结论HER-1和HER-2均在膀胱移行细胞癌中表达异常增加,其两者的表达为正相关性。HER-1的表达与膀胱尿路上皮癌的临床分期、病理分级、肿瘤复发相关。HER-2的表达与膀胱尿路上皮癌的临床分期和肿瘤复发相关。
第二章HER-1和HER-2双重酪氨酸激酶抑制剂Afatinib对膀胱癌T24细胞生物学行为的影响
目的研究Afatinib对T24细胞增殖、凋亡和侵袭能力的影响。
方法采用不同浓度的Afatinib (0,1,5,10,20umol/L)作用T24细胞,用MTT法研究Afatinib对T24细胞的增殖能力的影响；用流式细胞术(FCM)检测Afatinib对人膀胱癌T24细胞凋亡的影响；用细胞粘附实验检测Afatinib对人膀胱癌T24细胞对FN粘附的影响；用Transwell实验研究Afatinib对T24细胞的侵袭能力的影响；同时用western blot检测了侵袭相关蛋白MMP-2与MMP-9表达及凋亡相关蛋白Bcl-2与Bax的表达,通过检查ERK1/2和Akt探讨Afatinib作用于膀胱癌的机制。
结果Afatinib对膀胱癌T24细胞的增殖能力有着抑制作用；对T24细胞有着促进凋亡的作用,并且能改变T24细胞Bcl-2与Bax蛋白含量之比；Afatinib对膀胱癌T24细胞的侵袭能力有着抑制的作用,能抑制T24细胞MMP-2及MMP-9蛋白的表达；Afatinib作用于膀胱癌T24细胞后,p-ERK1/2和p-Akt蛋白呈下降趋势,且呈剂量依赖性；而对T24细胞的t-ERK1/2和t-Akt蛋白无影响。
结论Afatinib抑制了T24细胞的增殖和侵袭能力,促进了T24细胞的凋亡。
第三章Afatinib对膀胱癌T24细胞顺铂化疗敏感性研究
目的探讨Afatinib与顺铂联合应用于膀胱癌细胞的协同作用,并对其作用机制及耐药性进行初步探讨。
方法先进行膀胱癌T24-ADM细胞的制备,用MTT法观察Afatinib联合顺铂对T24细胞增殖的抑制作用；分别用MTT法检测Afatinib作用前后顺铂对T24-ADM细胞增殖的抑制作用；PCR法检测Afatinib作用前后顺铂对T24-ADM细胞MDR-1基因mRNA的表达水平；用western-blot法检测Afatinib作用前后顺铂对T24-ADM细胞p-gp的表达水平。
结果Afatinib和顺铂联合用药的T24细胞的增殖抑制率高于单用顺铂；顺铂对Afatinib作用后的T24-ADM细胞抑制率高于Afatinib作用前；经Afatinib作用后,mdr-1基因的表达和p-gp蛋白的水平都有下调。
结论Afatinib与顺铂同时作用膀胱癌T24细胞时,两者在抑制T24细胞增殖上表现出协同作用,Afatinib作用后顺铂对于膀胱T24-ADM细胞的抑制率高于单独用顺铂的抑制率,Afatinib能够有效抑制mdr-1基因的表达和p-gp蛋白的水平。
Part one The correlation between expression of HER-1/HER-2in bladder transitional cell carcinoma(BTCC) and clinical significance
Aim Explore the situation of expression of HER-1/HER-2in BTCC and evaluate the correlation between HER-1/HER-2with the parameters of BTCC such as tumor stage and grade.
Method The expression level of HER-1/HER-2was estimated by Immunohistochemistry technique. And the influence factors were also tested.
Result The positive rate of HER-1expression among56patients was55.4%, which was distinct higher than that in normal bladder tissue (10%); the positive rate of HER-2expression among56patients was37.5%, which was distinct higher than that in normal bladder tissue (0%); The expression level of HER-1was obvious greater in high stage group, high grade and relapse group than that in low stage group, low grade group and primary group. The expression level of HER-2was obvious greater in high stage group and relapse group than that in low stage group and primary group.
Conclusion The expression of HER-1/HER-2was up-regulated in BTCC, and their expression has the positive correlation.
Part two The influence of Afatinib on T24cells'biologic behavior
Aim Estimate the influence of Afatinib on T24cells'biologic behavior such as invasion, proliferation and apoptosis.
Method The T24cell was grouped depend on the concentration of Afatinib treatment (0,1,5,10,20umol/L). MTT was employed to evaluate the impact of Afatinib to T24proliferation; FCM was employed to evaluate the impact of Afatinib to T24with apoptosis ability; transwell analysis was used to detect the effect of Afatinib to T24invasion. The invasion associated protein MMP-2and MMP-9, the apoptosis associated protein Bcl-2and Bax was detected by western blot. Check the ERK1/2and Akt to explore the mechanism of the Afatinib in bladder cancer.
Result The T24cells showed more powerful repression of proliferation and invasion under the treatment of Afatinib. Afatinib could regulate the expression of MMP-2/MMP-9and BAX/Bcl-2proteins. Afatinib could promote the apoptosis ability of T24.
Conclusion Afatinib inhibition of T24cell proliferation and invasion and promotes apoptosis in T24cells.
Part three Afatinib influencing chemotherapy sensibility that cisplatin treat T24cell
Aim To research Afatinib influencing chemotherapy sensibility that cisplatin treat T24cell
Method First we prepared the T24-ADM cell, then observation of Afatinib combined with cisplatin on the inhibition of T24by MTT. Using the MTT to test sensibility of cisplatin before and after Afatinib used in T24-ADM cell. Using the PCR to test MDR-1before and after Afatinib used in T24-ADM cell and using the western-blot to test p-gp before and after Afatinib used in T24-ADM cell.
Result Combining Afatinib and cisplatin could of inhibit T24cell proliferation better than with cisplatin alone; cisplatin could of inhibit T24cell proliferation better if the Afatinib was used. Afatinib can inhibit the mdr-1gene and P-gp protein.
Conclusion Afatinib and cisplatin showed a synergistic effect in the inhibition of T24cell proliferation. Cisplatin could of inhibit T24cell proliferation better if the Afatinib was used. Afatinib can inhibit the mdr-1gene and P-gp protein.
引文
[1]Kwak C, Ku JH, Park JY, et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 Grade 3 bladder cancer. Journal of Urology,2004,10(1):149-152.
[2]Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res,2001,7(10):1850-1855.
[3]Fromowitz FB, Viola MV, Chao S, et al. Ras p21 expression in the progression of breast cancer. Hum Pathol,1987,18(12):1268-1275.
[4]Carpenter G, Cohen S. Epidermal growth factor. J BioChem,1990,265 (14):7709-7712
[5]Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol,2001,2(2):127-137
[6]Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors:an update of recent developments. Ann Surg Oncol,2007,14(2):942-943.
[7]Hynes NE, Lane HA. ErbB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer,2005,5(12):341-354.
[8]Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum,2007,50(8):1259-1270.
[9]Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol,2002,20 (18):1-13.
[10]Moscatello DK. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res,1995,55(10):5536-5539
[11]Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst,1998,90(12):824-832
[12]Knecht R, Peters S, Adunka O, et al. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res,2003,23(3B):2577-83.
[13]Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol, 2001,11(4):281-89
[14]Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer,2001,8(1):83-96
[15]Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of pro-EGF. Nature,1999,402(2):884-888
[16]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann NY Acad Sci,2000,9(2):249-264.
[17]Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct,2001,26(1):25-35.
[18]Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway:paradigms of multiplicity. Cell signal,2001,13(11):777-785.
[19]Araujo A, Ribeiro R, Azevedo I, et al. Genetic poly-morphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist,2007,12(2):201-210
[20]Kleeff J, Friess H, Berberat P, et al. Pancreatic cancer-new aspects of molecular biology research. Swiss Surg,2000,6(5):231-232
[21]Friess H, Yaanaka Y, Kobrin MS, et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression Clin Cancer Res,1995,1 (11):1413-1425.
[22]杨吉利,王长宏等EGFR、HER2、VEGF在胃癌组织中的表达及相关因素分析中国实验诊断学,2011,15(2)：247-250.
[23]Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer:a prospective comparative study. Eur Urol,1999,36(5):393-400.
[24]Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol,1995,153(3):919-925
[25]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU Int,1999,83(4):498-503.
[26]Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erb-B-2 gene product in patients with urinary bladde carcinoma. Cancer,1992, 70(3):2493-2498.
[27]Mellon JK, Lunec J, Wright C, et al. C-Erb-B2 in bladder cancer:molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol,1996,155(1):321-326.
[28]Wester K, Sjostrom A, Torre M, et al. HER-2:a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol,2002,41(3):282-288.
[29]Gandour-Edwards R, Lara P, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer,2002,95(10):1009-1015.
[30]Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci noma of the urinary bladder. Clin Cancer Res,2001,7(5):1957-1962.
[31]Kassouf W, Black PC, Tuziak T, et al. Distinctive expression patterns of ErbB family receptors signify an aggressive variant of bladder cancer [J]. J Urol,2007, 178(1) 1896-1900.
[32]王瑞,宋东奎,张卫星等.膀胱肿瘤表皮生长因子和受体表达的意义.中华外科杂志.1999,37(8)：477-478.
[33]Watanabe T, Shinohara N, Moriya K, et al. Significance of the Grb-2 and son of sevenless(Sos) protein in human bladder cancer cell. IUBMB Life,2000,49 (4): 317-320.
[34]周辉梁,罗义麒,曹林生等.原发性膀胱移行细胞癌PgP与突变p53蛋白、EGFR的相互关系.中国现代医学杂志,2001,11(2)：28-30.
[35]顾晓,元庚,徐正锉等.表皮生长因子受体在膀胱移行细胞癌中表达的意义.江苏临床医学杂志.2000；4(1)：1-3.
[36]Neal DE, Sharpies L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer,1990,65(5):1619-1625.
[37]Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. The Journal of Urology,1995, 153(2):919-925.
[38]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU International,1999,83(5):498-503.
[39]Skinner DG. Management of invasive bladder cancer:a meticulous pelvic node dissection can make a difference. J Urol,1982,128(1):34-36.
[40]Adjei AA, Rowinsky EK. Novel anticancer agents in clinical develop-pment. Cancer Biol Ther,2003,2(4):5-15.
[41]Jose L, Dominguez-Escrig, John D, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res,2004,10(7):4874-4884.
[42]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(2):51-56.
[43]Yang C, Shih J, Su W, et al. A phase II study of BIB W 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations(LUX-Lung 2). J Clin Oncol,2010,28 (15):7517-7521.
[44]Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1):a phase 2b/3 randomised trial. Lancet Oncol,2012 Mar 23. [Epub ahead of print].
[45]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinie. FASEB J,2004,18(7):790-804.
[46]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[47]SB Maddineni, VK Sangar, JH Hendry, et al. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinas inhibitor in two related bladder cancer cell lines. Br J Cancer,2005, 92(1):125-130.
[48]Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature,1996, 381(5):643-644.
[49]Sherr CJ, Roberts JM. CDK inhibitors:Positive and negative regulators of G1-Phase Progression. Genes Dev,1999,13(1):1501-1512.
[50]SherrCJ.GI Phase Progression:cycling on cue. Cell,1994,79(10):551-555.
[51]崔仑标,戴贵东,王心如.细胞周期素与膀胱癌关系的研究进展.中国肿瘤,2005,14(2)：111-114.
[52]Furukawa T, Kubota T, Suto A, et al. Clinical usefulnesss of chemosensitivity testing using the MTT assay. J Surs Oncol,1991,48(3):188-189.
[53]Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res,2003,63(10):8563-6872.
[54]Bukholm IR, Bukholm G, Nesland JM. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS,2002,110(3):214-220.
[55]Ohkouchi T, Sakuragi N, Watari H, et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol,2002,187(2):353-359.
[56]Zyada MM, Grawish ME, Elsabaa HM. Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma [J]. Ann Diagn Pathol,2009,13(5):313-322.
[57]Wang JM, Deng X, Gong W, et al. Chemokines and their role in tumor growth and metastasis [J]. J Immunol Methods,1998,220(1-2):1-17.
[58]Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis [J]. J Invest Dermatol,2002,118(6):915-922.
[59]Nicolson GL. Tumor microenvironment:paracrine and autocrine growth mechanisms and metastasis to specific sites [J]. Front Radiat Ther Oncol,1994, 28:11-24.
[60]Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis [J]. Cancer Metastasis Rev,1993,12(3-4):325-343
[61]Nakashio T, Natrita T, Sato M, et al. The association of metastasis with the expression of adhesion molecules in cell lines derived from human gastric cancer. Anti cancer Res,1997,17(IA):293-299.
[62]Jean D, Tellez C, Huang S, et al. Inhibition of tumor growth and metastasis of human melanoma by intraeellular anti-ATF-1 single chain Fv fragment. Oncogene,2000,19(22):2721 - 2730.
[63]Heimann R, Lan F, McBride R, et al. Separating favorable from unfavorable prognostic markers in breast cancer:the role of E-cadherin. Cancer Res,2000, 60(2):298-304.
[64]Hamasaki T, Hattori T, Kimura G, et al. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells [J]. Urol Res,1998,26(6):371-376.
[65]Kawakami S, Kageyama Y, Fujii Y, et al. Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells [J]. Anticancer Res,2001,21 (1 A):213-219.
[66]Nakopoulou L, Gakiopoulou H, Zervas A, et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer:a comparison with clinicopathologic features and survival[J]. Appl Immunohistochem Mol Morphol,2001, 9(2):130-137.
[67]Itoh M, Murata T, Suzuki T, et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells[J]. Oncogene,2006,25(8):1195-1204.
[68]Halbersztadt A, Halon A, Pajak J, et al. The role of matrix metalloproteinases in tumor invasion and metastasis[J]. Ginekol Pol,2006,77(1):63-71.
[69]Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers[J]. Biochimie,2005, 87(3-4):287-297.
[70]Kubben FJ, Sier CF, van Duijn W, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer [J]. Br J Cancer,2006,94 (7):1035-1040.
[71]Burg-Roderfeld M, Roderfeld M, Wagner S, et al. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol,2007, 30(4):985-92
[72]Kurallara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell careinoma of the oraleavity:correlations with tumor invasion and metastasis. Head Neek,1999,21(7):627-635.
[73]Hong SD, Hong SP, Lee JI et al. Expression of matrix metalloproteinase-2 and-9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol,2000,36(2):207-213.
[74]Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa,ZD1839) in non small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellur larsignal regulated kinase 112 and EGF receptor /Akt pathway for proliferat i on. Mol Cancer Ther,2004,3(1): 465-472.
[75]Bellmunt J, deWit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Cri t Rev Oncol Hematol,2003,47(2):195-206.
[76]James A, McCubrey, Linda S, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta,2007,73(17):1263-1284.
[77]Steelman SC, Pohnert JG, Shelton, et al. Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia,2004,18(3): 189-218.
[78]Kolch W, Kotwaliwale A, Vass K, et al.. The role of Raf kinases in malignant transformation. Expert Rev Mol Med,2002,20(2):1-18.
[79]Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia,2004,18(6).:628-635.
[80]Swiakowski S, Seifert HH, Steinhoff C, et al Activities of MAP-kinase pathways in normal urothelial cells and urothelial carcinoma cell lines. Exp Cell Res,2003,282(1) 48-57.
[81]Levesque P, Ramchurren N, Saini K, et al. Sreening of human bladder tumors and urine sediments for the presence of H-ras mutation.Int J Caneer,1993, 55(5):785-786.
[82]Burchill SA, Neal DE, Lunec J. Frequency of H-ras mutations in human bladder cancer detect by direct sequencing. BrJ Urol,1994,73(5):516-517.
[83]夏曙,于世英PI3K/Akt信号转导通路在恶性肿瘤中的研究进展.肿瘤,2006,26(6)：576—578.
[84]Cantley LC, Neel BG. New insights into tumor suppression:PTEN suppresse tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA,1999,96(8):4240-4245.
[85]Benistant C, Chapuis H, Roche S. A Specific function for Phosphatidylinositol 3-kinase alpha in cell survival and for Phosphatidytinositol 3-kinase bet in denovo DNA synthesis of human colon careinoma cells. Oncogene,2000, 19(44):5083-5090.
[86]Wu X, Obata T, Khan Q, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU lit,2004,93(1):143-150.
[87]Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol.2007,608(1):23-30.
[88]Miller VA, Hirsh V, Cadrane J, et al. Phase Ⅱ/Ⅲ double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2+best supportive care (BSC) versus placebo+ BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib(LUX-Lung1) [J]. Annals of Oncology,2010,21(8):1-12.
[89]Baseiga J, Albanell J, Ruiz A, et al. Phase Ⅱ and tumor Pharmacodynamic study of gefitinib in Patients with advanced breast cancer lines. J Clin Oncol, 2005,23(5):5323-5333.
[90]von Minekwitz G,Jonat W, Fasehing P, et al. A multicentre Phase Ⅱ study on gefitinib in taxane-and anthracyclinepretreated metastatic breast cancer[J]. Breast Cancer Res Treat,2005,89(2):165-172.
[91]Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa),an inhibitor of EGFR tyrosine kinase[J]. Clin Cancer Res, 2000,6(1):4885-4892.
[92]Koizumi F, Kanzawa F, Ueda Y, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib("Iressa") and the DNA to poisomerase Ⅰ inhibitor CPT-Ⅱ (irinotecan) in human colorectal cancer cells [J]. Int J Cancer,2004,108(4):464-472.
[93]Gomes AL, Melo FL, Werkhauser RP, et al. Development of a real time polymerase chain reaction for quantitation of Schistosoma mansoni DNA. Mem Inst Oswaldo Cruz.2006,101(1):133-136.
[94]Pader T, PKadanlbi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Scence,2002,296(12):1883-1886.
[95]Herr HW, Sehwalb DM, Zhang ZG, et al. Intravesical bacillus Chamette-Guerin therapy prevent tumor regression and death from superficial bladder cancer. J Clin Oncol,1995,13(6):1404-1408.
[96]Clifford SC, Thomas DJ, Neal DE, et al. Increased mdrl gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-bassde assay[J]. Br J Cancer,1994,69(4):680-686.
[97]王辉.肿瘤耐药基因的研究进展.国际病理科学与临床杂志,2007,27(3)：239—224.
[98]王琳,刘光明.肿瘤多药耐药逆转剂及逆转策略的研究进展.中国医院药学杂志,2006,26(40)：470-473.
[99]Ha SN, Hochman J, Sheridan RP. Mini review on molecular modeling of P-glycoprotein (Pgp). Curr Top Med Chem.2007;7(15):1525-1529.
[100]Gordon-cardo, O'Brien J P, Boccla J, et al. Expression of the multidrug resistance gene product(P-glycoprotein) in normal and tumor tissue. J Histochem Cytochem,1990,38:1277-1283.
[101]Benson MC, Giella J, Whang IS, et al. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder implications and applications [J]. J Urol,1991,146(4):982-987
[102]韩瑞发,吴长利,张广利等.膀胱癌多向耐药基因P-gp170的研究[J].中华泌尿外科杂志,1994,15(6)：419-421
[103]刘迎,曾甫清.膀胱肿瘤治疗中的多药耐药现象及逆转.临床泌尿外科杂志,2001,16：279-281.
[104]刘尚莹,张泓,曹晓明等.膀胱肿瘤多药耐药基因的表达及其临床意义.山西医药杂志,2000,29：97-99.
[105]Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HEPG2 cells by multidrug resistance gene (MDR1) antisense RNA. LifeSci,2000,67(17):2117-2124.
[106]Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1:a therapeutic target. Mol Interv,2001,1(5):117-125.
[107]Mayer LD, Lim KT, Hartley D. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance inP388/ADR cells expressing p-glycoprotein. J Exp Ther Oncol,2002,2(2):107-120.
[108]Zhang S, Wang J, Hirose K, et al. An efficient conversion of taxinine to taxinine NN-1, an anticancer agent and a modulator of multidrug-resistant tumor cells. J Nat prod,2002:65(12):1786-1792.
[109]Paez JG, Janne PA, Lee LC, et al. EGFR mutations in lung cancer:correlation with clinieal response to gefitinib therapy[J]. Secience,2004,304(2):1497-1500.
[110]Wang G, Reed E, Li QQ, et al. Molecular basis of cellular response to cisplatin chemotherpay in non-small cell lung cancer. Oncol Rep,2004, 12(5):955-965.
[111]Nutt JE, Lazarowicz HP, Mellon JK, et al. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer,2004,90(8):1679-1685.
[112]Schneeweiss A, Kolay S, Aulmann S, et al. Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs.2004, 15(3):235-238.
[113]Cameron D, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cance. N Engl J Med,2006,355 (1):2733-2743.
[114]Inoue K, Slaton JW, Perrotte P, et al Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody in Clone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res,2000,6(7):4874-4884.
[1]Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J ClinOncol,2002,20(18):1-13.
[2]Ciardiello F, Tortora G A novelapproach in the treatment of cancer:targeting the epidermal growth factor receptor. Clin Cancer Res,2001,7(8):2958-2970.
[3]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann N Y Acad Sci,2000,902(5):249-264.
[4]Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hemat,2008,65(2):9-10.
[5]Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors:an update of recent developments. Ann Surg Oncol,2007,14(2):942-943.
[6]Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum,2007,50(8):1259-1270.
[7]Yaden Y, Sliwkowskim X. Untangling the ErbB signaling net work[J]. Nat Rev Mol Cell Biol,2001,2(2):127-137.
[8]De Bono JS, Rowinsky EK. The ErbB receptor family:a therapeutic target for cancer. Trends Mol Med,2002,8(7):19-26.
[9]Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor over expression in esophageal carcinoma:An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer,1994,74(3): 795-804.
[10]Moscateuo Dk, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res,1995,55(23):5536-5539.
[11]Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the ⅴⅢ mutation of human epidermal growth factor receptor. Tumor BioL,2002,23(2): 61-69.
[12]Knecht R, Peters S, Adunka O, et al. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res,2003,23(3B):2577-2583.
[13]Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor ⅴⅢ as a molecular target in cancer therapy. Endocr Relat Cancer,2001,8(1):83-96.
[14]Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of profile-EGF. Nature,1999,402(7):884-888.
[15]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann N Y Acad Sci,2000,902(5):249-264.
[16]Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct,2001,26(1):25-35.
[17]Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway:paradigms of multiplicity. Cell signal,2001,13(11):777-785.
[18]Hynes NE, Lane HA. ErbB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer,2005,5(4):341-354.
[19]Haslekas C, Breen K, Pedersen KW, et al. The inhibitory effect of ErbB2 on EGF-induced formation of clathrin-coated pits correlates with retention of EGFR-ErbB2 oligomeric complexes at the Plasma membrane. Mol Biol Cell, 2005,16(6):5832-5842.
[20]Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in Primary osteosarcoma[J]. Cancer Res,2004,64(8):2047-2053.
[21]Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred eterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J,1997,16(7):1647-1650.
[22]Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmenbrane domain of p185. Cell,1986,45(5):649-657.
[23]Venter DJ, Tuzi NL, Kumar S, et al. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas:immunohistological assessment correlates with gene amplification. Lancet,1987,2(8550):69-72.
[24]Ravdin PM, Chamness GC. The c-erbB-2 proto—oncogene as a prognostic and predictive marker in breast cancer:A paradigm for the development of other macromolecular markers. Gene,1995,159(1):19-27.
[25]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(1):51-56.
[26]Batzer AG, Rotin D, UrenaJ M, et al. Hierarehy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Blol,1994,14 (7):5192-5201.
[27]Waters SB, Chen D, Kao AW, et al. Insulin and epidermal growth factor receptors regulate distinct Pools of Grb2-SOS in the control of Ras activation[J]. J Biol Chem,1996,271(1):18224-18230
[28]Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa,ZD1839) in non small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor /extracellur larsignal regulated kinase 1 12 and EGF receptor /Akt pathway for proliferation. Mol Cancer Ther,2004 3(7):465-472.
[29]Bellmunt J, dewit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol,2003,47(8):195-206.
[30]Johnson GL, Vaillancourt RR. Sequential protein kianse reactions controlling cell growth and differentiation. Curr Opin Cell Biol,1994,6(2):230-238.
[31]Steelman SC, Pohnert JG, Shelton, et al. Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia,2004,18 (4):189-218.
[32]Kolch W, Kotwaliwale A, Vass K, et al. The role of Raf kinases in malignant transformation. Expert Rev Mol Med,2002;20(2):1-18.
[33]Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia,2004,18(9):628-635.
[34]Datta SR, Brunet A, Greenberg ME. Cellular suvival:A play in three Akts. Genes Dev,1999,13(22):2905-2927.
[35]Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol,1998,10(2):262-267.
[36]Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol,2002,29(3):62-70.
[37]Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell,1998,2(4):405-415.
[38]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(2):51-56.
[39]Bclselga J. Clinical trial of signle agent Trastuzumab (Herceptin). Semin Oncol. 2000,27(5):20-26.
[40]Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for treatment of metastatic breast cancer[J]. Semin Oncol,2000, 27(6):38-45.
[41]Kate MK, Caroline MP. Trastuzumab:A review of its use in the treatment of metastatic breast cancer overexpresseing HER-2[J]. Drugs,2002,62 (1):209-243.
[42]Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. Clin Oncol,2002,20(3):1215-1221.
[43]Huang SM, Boek JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, poptosis and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res,1999,59(3):1935-1940.
[44]Mendelsohn J. Blockade of receptors for growth factors:An anticancer therapy [J]. Clin Cancer Res,2000,6(12):747-753.
[45]Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growthing orthotopically in nude mice by antiangiogenic mechanisms.[J]. Clin Cancer Res,2000,6(1):1936-1948.
[46]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinic. FASEB J,2004,18(7):790-804.
[47]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[48]Yang XD, Jia XC, Corvalan JR, et al. Development of ABX -EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy[J]. Crit Rev Oncol Hematol,2001,38(1):17-23.
[49]Ranson M. ZD1839(IRESSA):For more than just non-small cell lung cancer. The Oncologist,2002,7(4):16-20.
[50]Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor produc ion and angiogenesis in human cancer cells by ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 2001,7(5):1459-1465.
[51]Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor.C lin Cancer Res,2000,6(5):2053-2058.
[52]Woodbur JR, Barker AJ, Wakeling A, et al.6-Amino-4-(3-methyiphenyl amino)-quinazoline:an EGF receptor tyrosine kinase inhibitor with activity in a range of human turn or xenografts. Proc Am Assoc Cancer Res,1996,37(5): 390-395.
[53]Ciardiello F, Caputo R, Damiano V, et al. Potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an EGFR selective tyrosine kinase inhibitor. Proc Am Assoc Cancer Res,2000,41:482-487.
[54]Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated an dactive in patients with solid, malignant tumors:results of a phase I trial. J Clin Oncol, 2002,20(9):2240-2245.
[55]Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a Phase I interm it tent dose -escalation trial of ZD1839(Iressa) in Japanese patients with various solid tumors Proc Am Soc Clin Oncol,2001,20(5):324-328.
[56]Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 1995,19(1):183-187.
[57]Barton J, Blackledge G, Wakeling A. Growth factors and their receptors:new targets for prostate cancer therapy. Urology,2001,58(1):114-118
[58]Bence AK, Anderson EB, Halepeta MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs,2005,23(1):39-49.
[59]Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations[J]. Oncologist,2007,12(7):756-765.
[60]Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+breast cancer. Proc Am Soc Clin Oncol。2006,24(5): 18-21.
[61]Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647 inhibits murant forms of ErbB2 associated with lapatinib resistance and neoplastic transfor-mation[J]. Clin Cancer Res,2008,14(8):2465-2475.
[62]Yang C, Shih J, Su W, et al. A phase II study of BIB W 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations(LUX-Lung 2). J Clin Oncol,2010,28 (15):7517-7521.
[63]Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1):a phase 2b/3 randomised trial. Lancet Oncol,2012 Mar 23. [Epub ahead of print].
[64]Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumors. Br J Cancer.2008,98(1):80-85.
[65]Lewis N, Marshall J, Amelsberg A, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumours [abstract]. J Clin Oncol.2006,24(18):3091-3095.
[66]Janjigian Y, Groen H, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol.2011,29(15):7525-7528..
[67]Ang J, Mikropoulos C, Stavridi F, et al. A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol.2009,27(15):141-145.
[68]Awada A, Dumez H, Wolter P, et al. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. J Clin Oncol.2009,27(15):35-38.
[69]Bahleda R, Soria J, Berge Y, et al. Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. J Clin Oncol.2011,29(15):25-35.
[70]Vermorken J, Machiels J, Rottey S, et al. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid rumors. J Clin Oncol.2010,28 (4):135-138.
[71]Miller VA, Hirsh V, Cadranel J, et al. Phase Ⅱb/Ⅲ double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2+best supportive care (BSC) versus placebo+ BSC in patients with NSCLC failing 1 -2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Ann Oncol. 2010,21(8):8-14.
[72]Yang G, Shih J, Su W, et al. A phase Ⅱ study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). J Clin Oncol.2010,28(15):75-81.
[73]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU Int,1999,83(4):498-503.
[74]Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erb-B-2 gene product in patients with urinary bladde carcinoma. Cancer,1992, 70(3):2493-2498.
[75]Mellon JK, Lunec J, Wright C, et al. C-Erb-B2 in bladder cancer:molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol,1996,155(1):321-326.
[76]Wester K, Sjostrom A, Torre M, et al. HER-2:a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol,2002,41(3):282-288.
[77]Gandour-Edwards R, Lara P, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer,2002,95(10):1009-1015.
[78]Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci noma of the urinary bladder. Clin Cancer Res,2001,7(5):1957-1962.
[79]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinic. FASEB J,2004,18(7):790-804.
[80]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[81]SB Maddineni, VK Sangar, JH Hendry, et al. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinas inhibitor in two related bladder cancer cell lines. Br J Cancer,2005, 92(1):125-130.
[82]Hahn NM, Stadler WM, Zon R, et al. Mature results from Hoosier Oncology Group GU04-75 phase Ⅱ trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Society of Clinical Oncology. Annual Meeting; 2010. Chicago,.
[83]Hussain M, Vaishampayan U, Du W, et al Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol.2001,19(9):2527-2533.
[2]Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res,2001,7(10):1850-1855.
[3]Fromowitz FB, Viola MV, Chao S, et al. Ras p21 expression in the progression of breast cancer. Hum Pathol,1987,18(12):1268-1275.
[4]Carpenter G, Cohen S. Epidermal growth factor. J BioChem,1990,265 (14):7709-7712
[5]Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol,2001,2(2):127-137
[6]Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors:an update of recent developments. Ann Surg Oncol,2007,14(2):942-943.
[7]Hynes NE, Lane HA. ErbB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer,2005,5(12):341-354.
[8]Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum,2007,50(8):1259-1270.
[9]Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol,2002,20 (18):1-13.
[10]Moscatello DK. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res,1995,55(10):5536-5539
[11]Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst,1998,90(12):824-832
[12]Knecht R, Peters S, Adunka O, et al. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res,2003,23(3B):2577-83.
[13]Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol, 2001,11(4):281-89
[14]Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer,2001,8(1):83-96
[15]Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of pro-EGF. Nature,1999,402(2):884-888
[16]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann NY Acad Sci,2000,9(2):249-264.
[17]Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct,2001,26(1):25-35.
[18]Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway:paradigms of multiplicity. Cell signal,2001,13(11):777-785.
[19]Araujo A, Ribeiro R, Azevedo I, et al. Genetic poly-morphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist,2007,12(2):201-210
[20]Kleeff J, Friess H, Berberat P, et al. Pancreatic cancer-new aspects of molecular biology research. Swiss Surg,2000,6(5):231-232
[21]Friess H, Yaanaka Y, Kobrin MS, et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression Clin Cancer Res,1995,1 (11):1413-1425.
[22]杨吉利,王长宏等EGFR、HER2、VEGF在胃癌组织中的表达及相关因素分析中国实验诊断学,2011,15(2)：247-250.
[23]Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer:a prospective comparative study. Eur Urol,1999,36(5):393-400.
[24]Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol,1995,153(3):919-925
[25]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU Int,1999,83(4):498-503.
[26]Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erb-B-2 gene product in patients with urinary bladde carcinoma. Cancer,1992, 70(3):2493-2498.
[27]Mellon JK, Lunec J, Wright C, et al. C-Erb-B2 in bladder cancer:molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol,1996,155(1):321-326.
[28]Wester K, Sjostrom A, Torre M, et al. HER-2:a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol,2002,41(3):282-288.
[29]Gandour-Edwards R, Lara P, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer,2002,95(10):1009-1015.
[30]Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci noma of the urinary bladder. Clin Cancer Res,2001,7(5):1957-1962.
[31]Kassouf W, Black PC, Tuziak T, et al. Distinctive expression patterns of ErbB family receptors signify an aggressive variant of bladder cancer [J]. J Urol,2007, 178(1) 1896-1900.
[32]王瑞,宋东奎,张卫星等.膀胱肿瘤表皮生长因子和受体表达的意义.中华外科杂志.1999,37(8)：477-478.
[33]Watanabe T, Shinohara N, Moriya K, et al. Significance of the Grb-2 and son of sevenless(Sos) protein in human bladder cancer cell. IUBMB Life,2000,49 (4): 317-320.
[34]周辉梁,罗义麒,曹林生等.原发性膀胱移行细胞癌PgP与突变p53蛋白、EGFR的相互关系.中国现代医学杂志,2001,11(2)：28-30.
[35]顾晓,元庚,徐正锉等.表皮生长因子受体在膀胱移行细胞癌中表达的意义.江苏临床医学杂志.2000；4(1)：1-3.
[36]Neal DE, Sharpies L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer,1990,65(5):1619-1625.
[37]Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. The Journal of Urology,1995, 153(2):919-925.
[38]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU International,1999,83(5):498-503.
[39]Skinner DG. Management of invasive bladder cancer:a meticulous pelvic node dissection can make a difference. J Urol,1982,128(1):34-36.
[40]Adjei AA, Rowinsky EK. Novel anticancer agents in clinical develop-pment. Cancer Biol Ther,2003,2(4):5-15.
[41]Jose L, Dominguez-Escrig, John D, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res,2004,10(7):4874-4884.
[42]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(2):51-56.
[43]Yang C, Shih J, Su W, et al. A phase II study of BIB W 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations(LUX-Lung 2). J Clin Oncol,2010,28 (15):7517-7521.
[44]Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1):a phase 2b/3 randomised trial. Lancet Oncol,2012 Mar 23. [Epub ahead of print].
[45]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinie. FASEB J,2004,18(7):790-804.
[46]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[47]SB Maddineni, VK Sangar, JH Hendry, et al. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinas inhibitor in two related bladder cancer cell lines. Br J Cancer,2005, 92(1):125-130.
[48]Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature,1996, 381(5):643-644.
[49]Sherr CJ, Roberts JM. CDK inhibitors:Positive and negative regulators of G1-Phase Progression. Genes Dev,1999,13(1):1501-1512.
[50]SherrCJ.GI Phase Progression:cycling on cue. Cell,1994,79(10):551-555.
[51]崔仑标,戴贵东,王心如.细胞周期素与膀胱癌关系的研究进展.中国肿瘤,2005,14(2)：111-114.
[52]Furukawa T, Kubota T, Suto A, et al. Clinical usefulnesss of chemosensitivity testing using the MTT assay. J Surs Oncol,1991,48(3):188-189.
[53]Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res,2003,63(10):8563-6872.
[54]Bukholm IR, Bukholm G, Nesland JM. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS,2002,110(3):214-220.
[55]Ohkouchi T, Sakuragi N, Watari H, et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol,2002,187(2):353-359.
[56]Zyada MM, Grawish ME, Elsabaa HM. Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma [J]. Ann Diagn Pathol,2009,13(5):313-322.
[57]Wang JM, Deng X, Gong W, et al. Chemokines and their role in tumor growth and metastasis [J]. J Immunol Methods,1998,220(1-2):1-17.
[58]Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis [J]. J Invest Dermatol,2002,118(6):915-922.
[59]Nicolson GL. Tumor microenvironment:paracrine and autocrine growth mechanisms and metastasis to specific sites [J]. Front Radiat Ther Oncol,1994, 28:11-24.
[60]Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis [J]. Cancer Metastasis Rev,1993,12(3-4):325-343
[61]Nakashio T, Natrita T, Sato M, et al. The association of metastasis with the expression of adhesion molecules in cell lines derived from human gastric cancer. Anti cancer Res,1997,17(IA):293-299.
[62]Jean D, Tellez C, Huang S, et al. Inhibition of tumor growth and metastasis of human melanoma by intraeellular anti-ATF-1 single chain Fv fragment. Oncogene,2000,19(22):2721 - 2730.
[63]Heimann R, Lan F, McBride R, et al. Separating favorable from unfavorable prognostic markers in breast cancer:the role of E-cadherin. Cancer Res,2000, 60(2):298-304.
[64]Hamasaki T, Hattori T, Kimura G, et al. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells [J]. Urol Res,1998,26(6):371-376.
[65]Kawakami S, Kageyama Y, Fujii Y, et al. Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells [J]. Anticancer Res,2001,21 (1 A):213-219.
[66]Nakopoulou L, Gakiopoulou H, Zervas A, et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer:a comparison with clinicopathologic features and survival[J]. Appl Immunohistochem Mol Morphol,2001, 9(2):130-137.
[67]Itoh M, Murata T, Suzuki T, et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells[J]. Oncogene,2006,25(8):1195-1204.
[68]Halbersztadt A, Halon A, Pajak J, et al. The role of matrix metalloproteinases in tumor invasion and metastasis[J]. Ginekol Pol,2006,77(1):63-71.
[69]Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers[J]. Biochimie,2005, 87(3-4):287-297.
[70]Kubben FJ, Sier CF, van Duijn W, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer [J]. Br J Cancer,2006,94 (7):1035-1040.
[71]Burg-Roderfeld M, Roderfeld M, Wagner S, et al. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol,2007, 30(4):985-92
[72]Kurallara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell careinoma of the oraleavity:correlations with tumor invasion and metastasis. Head Neek,1999,21(7):627-635.
[73]Hong SD, Hong SP, Lee JI et al. Expression of matrix metalloproteinase-2 and-9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol,2000,36(2):207-213.
[74]Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa,ZD1839) in non small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellur larsignal regulated kinase 112 and EGF receptor /Akt pathway for proliferat i on. Mol Cancer Ther,2004,3(1): 465-472.
[75]Bellmunt J, deWit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Cri t Rev Oncol Hematol,2003,47(2):195-206.
[76]James A, McCubrey, Linda S, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta,2007,73(17):1263-1284.
[77]Steelman SC, Pohnert JG, Shelton, et al. Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia,2004,18(3): 189-218.
[78]Kolch W, Kotwaliwale A, Vass K, et al.. The role of Raf kinases in malignant transformation. Expert Rev Mol Med,2002,20(2):1-18.
[79]Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia,2004,18(6).:628-635.
[80]Swiakowski S, Seifert HH, Steinhoff C, et al Activities of MAP-kinase pathways in normal urothelial cells and urothelial carcinoma cell lines. Exp Cell Res,2003,282(1) 48-57.
[81]Levesque P, Ramchurren N, Saini K, et al. Sreening of human bladder tumors and urine sediments for the presence of H-ras mutation.Int J Caneer,1993, 55(5):785-786.
[82]Burchill SA, Neal DE, Lunec J. Frequency of H-ras mutations in human bladder cancer detect by direct sequencing. BrJ Urol,1994,73(5):516-517.
[83]夏曙,于世英PI3K/Akt信号转导通路在恶性肿瘤中的研究进展.肿瘤,2006,26(6)：576—578.
[84]Cantley LC, Neel BG. New insights into tumor suppression:PTEN suppresse tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA,1999,96(8):4240-4245.
[85]Benistant C, Chapuis H, Roche S. A Specific function for Phosphatidylinositol 3-kinase alpha in cell survival and for Phosphatidytinositol 3-kinase bet in denovo DNA synthesis of human colon careinoma cells. Oncogene,2000, 19(44):5083-5090.
[86]Wu X, Obata T, Khan Q, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU lit,2004,93(1):143-150.
[87]Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol.2007,608(1):23-30.
[88]Miller VA, Hirsh V, Cadrane J, et al. Phase Ⅱ/Ⅲ double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2+best supportive care (BSC) versus placebo+ BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib(LUX-Lung1) [J]. Annals of Oncology,2010,21(8):1-12.
[89]Baseiga J, Albanell J, Ruiz A, et al. Phase Ⅱ and tumor Pharmacodynamic study of gefitinib in Patients with advanced breast cancer lines. J Clin Oncol, 2005,23(5):5323-5333.
[90]von Minekwitz G,Jonat W, Fasehing P, et al. A multicentre Phase Ⅱ study on gefitinib in taxane-and anthracyclinepretreated metastatic breast cancer[J]. Breast Cancer Res Treat,2005,89(2):165-172.
[91]Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa),an inhibitor of EGFR tyrosine kinase[J]. Clin Cancer Res, 2000,6(1):4885-4892.
[92]Koizumi F, Kanzawa F, Ueda Y, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib("Iressa") and the DNA to poisomerase Ⅰ inhibitor CPT-Ⅱ (irinotecan) in human colorectal cancer cells [J]. Int J Cancer,2004,108(4):464-472.
[93]Gomes AL, Melo FL, Werkhauser RP, et al. Development of a real time polymerase chain reaction for quantitation of Schistosoma mansoni DNA. Mem Inst Oswaldo Cruz.2006,101(1):133-136.
[94]Pader T, PKadanlbi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Scence,2002,296(12):1883-1886.
[95]Herr HW, Sehwalb DM, Zhang ZG, et al. Intravesical bacillus Chamette-Guerin therapy prevent tumor regression and death from superficial bladder cancer. J Clin Oncol,1995,13(6):1404-1408.
[96]Clifford SC, Thomas DJ, Neal DE, et al. Increased mdrl gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-bassde assay[J]. Br J Cancer,1994,69(4):680-686.
[97]王辉.肿瘤耐药基因的研究进展.国际病理科学与临床杂志,2007,27(3)：239—224.
[98]王琳,刘光明.肿瘤多药耐药逆转剂及逆转策略的研究进展.中国医院药学杂志,2006,26(40)：470-473.
[99]Ha SN, Hochman J, Sheridan RP. Mini review on molecular modeling of P-glycoprotein (Pgp). Curr Top Med Chem.2007;7(15):1525-1529.
[100]Gordon-cardo, O'Brien J P, Boccla J, et al. Expression of the multidrug resistance gene product(P-glycoprotein) in normal and tumor tissue. J Histochem Cytochem,1990,38:1277-1283.
[101]Benson MC, Giella J, Whang IS, et al. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder implications and applications [J]. J Urol,1991,146(4):982-987
[102]韩瑞发,吴长利,张广利等.膀胱癌多向耐药基因P-gp170的研究[J].中华泌尿外科杂志,1994,15(6)：419-421
[103]刘迎,曾甫清.膀胱肿瘤治疗中的多药耐药现象及逆转.临床泌尿外科杂志,2001,16：279-281.
[104]刘尚莹,张泓,曹晓明等.膀胱肿瘤多药耐药基因的表达及其临床意义.山西医药杂志,2000,29：97-99.
[105]Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HEPG2 cells by multidrug resistance gene (MDR1) antisense RNA. LifeSci,2000,67(17):2117-2124.
[106]Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1:a therapeutic target. Mol Interv,2001,1(5):117-125.
[107]Mayer LD, Lim KT, Hartley D. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance inP388/ADR cells expressing p-glycoprotein. J Exp Ther Oncol,2002,2(2):107-120.
[108]Zhang S, Wang J, Hirose K, et al. An efficient conversion of taxinine to taxinine NN-1, an anticancer agent and a modulator of multidrug-resistant tumor cells. J Nat prod,2002:65(12):1786-1792.
[109]Paez JG, Janne PA, Lee LC, et al. EGFR mutations in lung cancer:correlation with clinieal response to gefitinib therapy[J]. Secience,2004,304(2):1497-1500.
[110]Wang G, Reed E, Li QQ, et al. Molecular basis of cellular response to cisplatin chemotherpay in non-small cell lung cancer. Oncol Rep,2004, 12(5):955-965.
[111]Nutt JE, Lazarowicz HP, Mellon JK, et al. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer,2004,90(8):1679-1685.
[112]Schneeweiss A, Kolay S, Aulmann S, et al. Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs.2004, 15(3):235-238.
[113]Cameron D, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cance. N Engl J Med,2006,355 (1):2733-2743.
[114]Inoue K, Slaton JW, Perrotte P, et al Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody in Clone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res,2000,6(7):4874-4884.
[1]Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J ClinOncol,2002,20(18):1-13.
[2]Ciardiello F, Tortora G A novelapproach in the treatment of cancer:targeting the epidermal growth factor receptor. Clin Cancer Res,2001,7(8):2958-2970.
[3]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann N Y Acad Sci,2000,902(5):249-264.
[4]Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hemat,2008,65(2):9-10.
[5]Steeghs N, Nortier JWR, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors:an update of recent developments. Ann Surg Oncol,2007,14(2):942-943.
[6]Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum,2007,50(8):1259-1270.
[7]Yaden Y, Sliwkowskim X. Untangling the ErbB signaling net work[J]. Nat Rev Mol Cell Biol,2001,2(2):127-137.
[8]De Bono JS, Rowinsky EK. The ErbB receptor family:a therapeutic target for cancer. Trends Mol Med,2002,8(7):19-26.
[9]Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor over expression in esophageal carcinoma:An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer,1994,74(3): 795-804.
[10]Moscateuo Dk, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res,1995,55(23):5536-5539.
[11]Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the ⅴⅢ mutation of human epidermal growth factor receptor. Tumor BioL,2002,23(2): 61-69.
[12]Knecht R, Peters S, Adunka O, et al. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res,2003,23(3B):2577-2583.
[13]Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor ⅴⅢ as a molecular target in cancer therapy. Endocr Relat Cancer,2001,8(1):83-96.
[14]Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of profile-EGF. Nature,1999,402(7):884-888.
[15]Carmeliet P, Collen D. Molecular basis of angiogenesis:Role of VEGF and VE-cadherin. Ann N Y Acad Sci,2000,902(5):249-264.
[16]Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct,2001,26(1):25-35.
[17]Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway:paradigms of multiplicity. Cell signal,2001,13(11):777-785.
[18]Hynes NE, Lane HA. ErbB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer,2005,5(4):341-354.
[19]Haslekas C, Breen K, Pedersen KW, et al. The inhibitory effect of ErbB2 on EGF-induced formation of clathrin-coated pits correlates with retention of EGFR-ErbB2 oligomeric complexes at the Plasma membrane. Mol Biol Cell, 2005,16(6):5832-5842.
[20]Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in Primary osteosarcoma[J]. Cancer Res,2004,64(8):2047-2053.
[21]Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred eterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J,1997,16(7):1647-1650.
[22]Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmenbrane domain of p185. Cell,1986,45(5):649-657.
[23]Venter DJ, Tuzi NL, Kumar S, et al. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas:immunohistological assessment correlates with gene amplification. Lancet,1987,2(8550):69-72.
[24]Ravdin PM, Chamness GC. The c-erbB-2 proto—oncogene as a prognostic and predictive marker in breast cancer:A paradigm for the development of other macromolecular markers. Gene,1995,159(1):19-27.
[25]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(1):51-56.
[26]Batzer AG, Rotin D, UrenaJ M, et al. Hierarehy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Blol,1994,14 (7):5192-5201.
[27]Waters SB, Chen D, Kao AW, et al. Insulin and epidermal growth factor receptors regulate distinct Pools of Grb2-SOS in the control of Ras activation[J]. J Biol Chem,1996,271(1):18224-18230
[28]Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa,ZD1839) in non small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor /extracellur larsignal regulated kinase 1 12 and EGF receptor /Akt pathway for proliferation. Mol Cancer Ther,2004 3(7):465-472.
[29]Bellmunt J, dewit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol,2003,47(8):195-206.
[30]Johnson GL, Vaillancourt RR. Sequential protein kianse reactions controlling cell growth and differentiation. Curr Opin Cell Biol,1994,6(2):230-238.
[31]Steelman SC, Pohnert JG, Shelton, et al. Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia,2004,18 (4):189-218.
[32]Kolch W, Kotwaliwale A, Vass K, et al. The role of Raf kinases in malignant transformation. Expert Rev Mol Med,2002;20(2):1-18.
[33]Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia,2004,18(9):628-635.
[34]Datta SR, Brunet A, Greenberg ME. Cellular suvival:A play in three Akts. Genes Dev,1999,13(22):2905-2927.
[35]Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol,1998,10(2):262-267.
[36]Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol,2002,29(3):62-70.
[37]Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell,1998,2(4):405-415.
[38]Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco,2001,56(2):51-56.
[39]Bclselga J. Clinical trial of signle agent Trastuzumab (Herceptin). Semin Oncol. 2000,27(5):20-26.
[40]Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for treatment of metastatic breast cancer[J]. Semin Oncol,2000, 27(6):38-45.
[41]Kate MK, Caroline MP. Trastuzumab:A review of its use in the treatment of metastatic breast cancer overexpresseing HER-2[J]. Drugs,2002,62 (1):209-243.
[42]Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. Clin Oncol,2002,20(3):1215-1221.
[43]Huang SM, Boek JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, poptosis and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res,1999,59(3):1935-1940.
[44]Mendelsohn J. Blockade of receptors for growth factors:An anticancer therapy [J]. Clin Cancer Res,2000,6(12):747-753.
[45]Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growthing orthotopically in nude mice by antiangiogenic mechanisms.[J]. Clin Cancer Res,2000,6(1):1936-1948.
[46]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinic. FASEB J,2004,18(7):790-804.
[47]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[48]Yang XD, Jia XC, Corvalan JR, et al. Development of ABX -EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy[J]. Crit Rev Oncol Hematol,2001,38(1):17-23.
[49]Ranson M. ZD1839(IRESSA):For more than just non-small cell lung cancer. The Oncologist,2002,7(4):16-20.
[50]Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor produc ion and angiogenesis in human cancer cells by ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 2001,7(5):1459-1465.
[51]Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor.C lin Cancer Res,2000,6(5):2053-2058.
[52]Woodbur JR, Barker AJ, Wakeling A, et al.6-Amino-4-(3-methyiphenyl amino)-quinazoline:an EGF receptor tyrosine kinase inhibitor with activity in a range of human turn or xenografts. Proc Am Assoc Cancer Res,1996,37(5): 390-395.
[53]Ciardiello F, Caputo R, Damiano V, et al. Potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an EGFR selective tyrosine kinase inhibitor. Proc Am Assoc Cancer Res,2000,41:482-487.
[54]Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated an dactive in patients with solid, malignant tumors:results of a phase I trial. J Clin Oncol, 2002,20(9):2240-2245.
[55]Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a Phase I interm it tent dose -escalation trial of ZD1839(Iressa) in Japanese patients with various solid tumors Proc Am Soc Clin Oncol,2001,20(5):324-328.
[56]Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 1995,19(1):183-187.
[57]Barton J, Blackledge G, Wakeling A. Growth factors and their receptors:new targets for prostate cancer therapy. Urology,2001,58(1):114-118
[58]Bence AK, Anderson EB, Halepeta MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs,2005,23(1):39-49.
[59]Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations[J]. Oncologist,2007,12(7):756-765.
[60]Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+breast cancer. Proc Am Soc Clin Oncol。2006,24(5): 18-21.
[61]Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647 inhibits murant forms of ErbB2 associated with lapatinib resistance and neoplastic transfor-mation[J]. Clin Cancer Res,2008,14(8):2465-2475.
[62]Yang C, Shih J, Su W, et al. A phase II study of BIB W 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations(LUX-Lung 2). J Clin Oncol,2010,28 (15):7517-7521.
[63]Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1):a phase 2b/3 randomised trial. Lancet Oncol,2012 Mar 23. [Epub ahead of print].
[64]Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumors. Br J Cancer.2008,98(1):80-85.
[65]Lewis N, Marshall J, Amelsberg A, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumours [abstract]. J Clin Oncol.2006,24(18):3091-3095.
[66]Janjigian Y, Groen H, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol.2011,29(15):7525-7528..
[67]Ang J, Mikropoulos C, Stavridi F, et al. A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol.2009,27(15):141-145.
[68]Awada A, Dumez H, Wolter P, et al. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. J Clin Oncol.2009,27(15):35-38.
[69]Bahleda R, Soria J, Berge Y, et al. Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. J Clin Oncol.2011,29(15):25-35.
[70]Vermorken J, Machiels J, Rottey S, et al. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid rumors. J Clin Oncol.2010,28 (4):135-138.
[71]Miller VA, Hirsh V, Cadranel J, et al. Phase Ⅱb/Ⅲ double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2+best supportive care (BSC) versus placebo+ BSC in patients with NSCLC failing 1 -2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Ann Oncol. 2010,21(8):8-14.
[72]Yang G, Shih J, Su W, et al. A phase Ⅱ study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). J Clin Oncol.2010,28(15):75-81.
[73]Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression:predictive value for the outcome after cystectomy for bladder cancer? BJU Int,1999,83(4):498-503.
[74]Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erb-B-2 gene product in patients with urinary bladde carcinoma. Cancer,1992, 70(3):2493-2498.
[75]Mellon JK, Lunec J, Wright C, et al. C-Erb-B2 in bladder cancer:molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol,1996,155(1):321-326.
[76]Wester K, Sjostrom A, Torre M, et al. HER-2:a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol,2002,41(3):282-288.
[77]Gandour-Edwards R, Lara P, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer,2002,95(10):1009-1015.
[78]Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci noma of the urinary bladder. Clin Cancer Res,2001,7(5):1957-1962.
[79]Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinic. FASEB J,2004,18(7):790-804.
[80]Perrotte P, Matsumoto T, Inoue K, et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogen is in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res,1999,5(2):257-265.
[81]SB Maddineni, VK Sangar, JH Hendry, et al. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinas inhibitor in two related bladder cancer cell lines. Br J Cancer,2005, 92(1):125-130.
[82]Hahn NM, Stadler WM, Zon R, et al. Mature results from Hoosier Oncology Group GU04-75 phase Ⅱ trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Society of Clinical Oncology. Annual Meeting; 2010. Chicago,.
[83]Hussain M, Vaishampayan U, Du W, et al Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol.2001,19(9):2527-2533.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |